- About Us
- Why Partner
-
Pipeline
- Marketed Products
- Priligy®
- Nesina®
- Oseni® and Liovel®
- Kazano®
- Discovery/Development
Pipeline - Eluxadoline (Mudelta)
- Novel Fluoroquinolone JNJ-Q2
- SYR-472
Trelagliptin
- Investors
- News
- Contact
SEC Filings
| Filing | Description | Date Filed  |
Size | ||||
|---|---|---|---|---|---|---|---|
| 10-Q | quarterly report | 05-09-2013 | 231.4 KB | ||||
| 8-K | current report | 05-07-2013 | 61.3 KB | ||||
| DEFA14A | definitive proxy statement | 04-11-2013 | 143.6 KB | ||||
| DEF 14A | definitive proxy statement | 04-11-2013 | 480.5 KB | ||||
| 8-K | current report | 04-09-2013 | 40.0 KB | ||||
| 10-K | annual report | 03-18-2013 | 831.5 KB | ||||
| 4/A | kaldor stephen w | 03-14-2013 | 33.7 KB | ||||
| 4/A | ruscher robert p | 03-14-2013 | 37.2 KB | ||||
| 4 | ruscher, robert p | 03-13-2013 | 28.6 KB | ||||
| 4 | kaldor, stephen w | 03-13-2013 | 28.1 KB | ||||
| 8-K | current report | 03-06-2013 | 66.3 KB | ||||
| 3 | artal group s.a. | 02-19-2013 | 26.2 KB | ||||
| SC 13G/A | amended statement of beneficial ownership | 02-19-2013 | 59.7 KB | ||||
| CT ORDER | confidential treatment order | 02-15-2013 | 7.1 KB | ||||
| SC 13G/A | amended statement of beneficial ownership | 02-14-2013 | 79.9 KB | ||||
| 10-Q/A | amended quarterly report | 02-12-2013 | 678.5 KB | ||||
| SC 13G/A | amended statement of beneficial ownership | 02-08-2013 | 26.2 KB | ||||
| SC 13G/A | amended statement of beneficial ownership | 01-31-2013 | 60.5 KB | ||||
| SC 13G/A | amended statement of beneficial ownership | 01-31-2013 | 64.6 KB | ||||
| 8-K | current report | 01-28-2013 | 40.7 KB | ||||
|
|||||||